|
1
|
Moresco RN, Speeckaert MM and Delanghe JR:
Diagnosis and monitoring of IgA nephropathy: The role of biomarkers
as an alternative to renal biopsy. Autoimmun Rev. 14:847–853. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fabiano RC, Pinheiro SV and Simões E Silva
AC: Immunoglobulin A nephropathy: A pathophysiology view. Inflamm
Res. 65:757–770. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
KDIGO clinical practice guidelines for
glomerulonephritis, . 2012.Chapter 10: Immunoglobulin A
nephropathy. Kidney Int Suppl. 2:S209–S217. View Article : Google Scholar
|
|
4
|
Glassock RJ: Glomerular disease: Targeted
steroid therapy for IgA nephropathy. Nat Rev Nephron. 13:390–392.
2017. View Article : Google Scholar
|
|
5
|
Suzuki Y, Suzuki H, Makita Y, Takahata A,
Takahashi K, Muto M, Sasaki Y, Kelimu A, Matsuzaki K, Yanagawa H,
et al: Diagnosis and activity assessment of immunoglobulin A
nephropathy: Current perspectives on noninvasive testing with
aberrantly glycosylated immunoglobulin A-related biomarkers. Int J
Nephrol Renovasc Dis. 7:409–414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yeo SC, Cheung CK and Barratt J: New
insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol.
33:763–777. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Robert T, Berthelot L, Cambier A, Rondeau
E and Monteiro RC: Molecular insights into the pathogenesis of IgA
nephropathy. Trends Mol Med. 21:762–775. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu S, Bao H, Xu X, Zhou X, Qin W, Zeng C
and Liu Z: Increased miR-374b promotes cell proliferation and the
production of aberrant glycosylated IgA1 in B cells of IgA
nephropathy. FEBS Lett. 589:4019–4025. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suzuki H, Allegri L, Suzuki Y, Hall S,
Moldoveanu Z, Wyatt RJ, Novak J and Julian BA: Galactose-deficient
IgA1 as a candidate urinary polypeptide marker of IgA nephropathy?
Dis Markers 2016. 78064382016.
|
|
10
|
Knoppova B, Reily C, Maillard N, Rizk DV,
Moldoveanu Z, Mestecky J, Raska M, Renfrow MB, Julian BA and Novak
J: The origin and activities of IgA1-containing immune complexes in
IgA nephropathy. Front Immunol. 7:1172016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Suzuki H, Fan R, Zhang Z, Brown R, Hall S,
Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, et al:
Aberrantly glycosylated IgA1 in IgA nephropathy patients is
recognized by IgG antibodies with restricted heterogeneity. J Clin
Invest. 119:1668–1677. 2009.PubMed/NCBI
|
|
12
|
Tomino Y, Sakai H, Miura M, Endoh M and
Nomoto Y: Detection of polymeric IgA in glomeruli from patients
with IgA nephropathy. Clin Exp Immunol. 49:419–425. 1982.PubMed/NCBI
|
|
13
|
Lai KN, Ho RT, Leung JC, Lai FM and Li PK:
Increased mRNA encoding for transforming factor-beta in CD4+ cells
from patients with Ig Anephropathy. Kidney Int. 46:862–868. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Batra A, Smith AC, Feehally J and Barratt
J: T-cell homing receptor expression in IgA nephropathy. Nephrol
Nephrol Dial Transplant. 22:2540–2548. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lai KN, Ho RT, Leung JC, Chui YL, Lim PL,
Lui SF and Li PK: CD4-positive cells from patients with IgA
nephropathy demonstrate increased mRNA of cytokines that induce the
IgA switch and differentiation. J Pathol. 174:13–22. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haas M: Histologic subclassification of
IgA nephropathy: A clinicopathologic study of 244 cases. Am J
Kidney Dis. 6:829–842. 1997. View Article : Google Scholar
|
|
17
|
Katafuchi R, Kiyoshi Y, Oh Y, Uesugi N,
Ikeda K, Yanase T and Fujimi S: Glomerular score as a
prognosticator in IgA nephropathy: Its usefulness and limitation.
Clin Nephrol. 49:1–8. 1998.PubMed/NCBI
|
|
18
|
Zhu Y, Ye X, Zhu B, Pei X, Wei L, Wu J and
Zhao W: Comparisons between the 2012 New CKD-EPI (ChronicKidney
Disease Epidemiology Collaboration) equations and other four
approved equations. PLoS One. 9:e846882014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Szeto CC and Li PK: MicroRNAs in IgA
nephropathy. Nat Rev Nephrol. 10:249–256. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rasche FM, Keller F, Rasche WG, Schiekofer
S, Boldt A, Sack U and Fahnert J: Why, when and how should
immunosuppressive therapy considered in patients with
immunoglobulin A nephropathy? Clin Exp Immunol. 186:115–133. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park KS, Han SH, Kie JH, Nam KH, Lee MJ,
Lim BJ, Kwon YE, Kim YL, An SY, Kim CH, et al: Comparison of the
Haas and the Oxford classifications for prediction of renal outcome
in patients with IgA nephropathy. Hum Pathol. 45:236–243. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee SM, Rao VM, Franklin WA, Schiffer MS,
Aronson AJ, Spargo BH and Katz AI: IgA nephropathy: Morphologic
predictors of progressive renal disease. HUM Pathol. 13:314–22.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haas M and Reich HN: Morphologic markers
of progressive immunoglobulin A nephropathy. Adv Chronic Kidney
Dis. 19:107–113. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pozzi C: Treatment of IgA nephropathy. J
Nephrol. 29:21–25. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chakera A, MacEwen C, Bellur SS, Chompuk
LO, Lunn D and Roberts ISD: Prognostic value of endocapillary
hypercellularity in IgA nephropathy patients with no
immunosuppression. J Nephrol. 29:367–375. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
O'Shaughnessy MM and Lafayette RA:
Corticosteroids for IgA Nephropathy: TESTING for Benefit,
Discovering Harm. JAMA. 318:429–431. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Coppo R, Lofaro D, Camilla RR, Bellur S,
Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, et al:
Risk factors for progression in children and young adults with IgA
nephropathy: An analysis of 261 cases from the VALIGA European
cohort. Pediatr Nephrol. 32:139–150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eitner F, Ackermann D, Hilgers RD and
Floege J: Supportive versus immunosuppressive therapy of
progressive IgA nephropathy (STOP) IgAN trial: Rationale and study
protocol. J Nephrol. 21:284–289. 2008.PubMed/NCBI
|
|
29
|
Nagy J, Sági B, Máté J, Vas T and Kovács
T: Considerations on the treatment of IgA nephropathy on the basis
of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN).
Orv Hetil. 158:1946–1952. 2017.(In Hungarian). View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alvarado AS, Andeen NK, Brodsky S, Hinton
A, Nadasdy T, Alpers CE, Blosser C, Najafian B and Rovin BH:
Location of glomerular immune deposits, not codeposition of
immunoglobulin G, influences definitive renal outcomes in
immunoglobulin A nephropathy. Nephrol Dial Transplant.
33:1168–1175. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kiryluk K, Li Y, Moldoveanu Z, Suzuki H,
Reily C, Hou P, Xie J, Mladkova N, Prakash S, Fischman C, et al:
GWAS for serum galactose-deficient IgA1 implicates critical genes
of the O-glycosylation pathway. PLoS Genet. 13:e10066092017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stuchlova Horynova M, Vrablikova A,
Stewart TJ, Takahashi K, Czernekova L, Yamada K, Suzuki H, Julian
BA, Renfrow MB, Novak J and Raska M: N-acetylgalactosaminide
α2,6-sialyltransferase II is a candidate enzyme for sialylation of
galactose-deficient IgA1, the key autoantigen in IgA nephropathy.
Nephrol Dial Transplant. 30:234–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kiryluk K and Novak J: The genetics and
immunobiology of IgA nephropathy. J Clin Invest. 124:2325–2332.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ye M, Peng Y, Liu C, Yan W, Peng X, He L,
Liu H and Liu F: Vibration induces BAFF overexpression and aberrant
O-Glycosylation of IgA1 in cultured human tonsillar mononuclear
cells in IgA nephropathy. Biomed Res Int. 2016:91259602016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ju T and Cummings RD: A unique molecular
chaperone Cosmc required for activity of the mammalian core 1 beta
3-galactosyltransferase. Proc Natl Acad Sci USA. 99:pp.
16613–16618. 2002; View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Meng H, Ohtake H, Ishida A, Ohta N,
Kakehata S and Yamakawa M: IgA production and tonsillar focal
infection in IgA nephropathy. J Clin Exp Hematop. 52:161–170. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Neurath MF, Finotto S and Glimcher LH: The
role of Th1/Th2 polarization in mucosal immunity. Nat Med.
8:567–573. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
He L, Peng Y, Liu H, Yin W, Chen X, Peng
X, Shao J, Liu Y and Liu F: Activation of the interleukin-4/signal
transducer and activator of transcription 6 signaling pathway and
homeodomain-interacting protein kinase 2 production by tonsillar
mononuclear cells in IgA nephropathy. Am J Nephrol. 38:321–332.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu L, Kou P, Zeng Q, Pei G, Li Y, Liang
H, Xu G and Chen S: CD4+ T Lymphocytes, especially Th2 cells,
contribute to the progress of renal fibrosis. Am J Nephrol.
36:386–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yamada K, Kobayashi N, Ikeda T, Suzuki Y,
Tsuge T, Horikoshi S, Emancipator SN and Tomino Y: Down-regulation
of core 1 beta 1, 3-galactosylatransferase and Cosmc by Th2
cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant.
25:3890–3897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Suzuki H, Suzuki Y, Aizawa M, Yamanaka T,
Kihara M, Pang H, Horikoshi S and Tomino Y: Th1 polarization in
murine IgA nephropathy directed by bone marrow-derived cells.
Kidney Int. 72:319–327. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lin FJ, Jiang GR, Shan JP, Zhu C, Zou J
and Wu XR: Imbalance of regulatory T cells to Th17 cells in IgA
nephropathy. Scand J Clin Lab Invest. 72:221–229. 2010. View Article : Google Scholar
|
|
43
|
Huang H, Peng Y, Liu H, Yang X and Liu F:
Decreased CD4+CD25+ cells and increased dimeric IgA-producing cells
in tonsils in IgA nephropathy. J Nephrol. 23:202–209.
2010.PubMed/NCBI
|
|
44
|
Chen X, Tang Y, Zhang Y, Zhuo M, Tang Z,
Yu Y and Zang G: Tapasin modification on the intracellular epitope
HBcAg18-27 enhances HBV-specific CTL immune response and inhibits
hepatitis B virus replication in vivo. Lab Invest. 94:478–490.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Quintás-Cardama A and Verstovsek S:
Molecular pathways: Jak/STAT pathway: Mutations, inhibitors, and
resistance. Clin Cancer Res. 19:1933–1940. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shea-Donohue T, Fasano A, Smith A and Zhao
A: Enteric pathogens and gut function: Role of cytokines and STATs.
Gut Microbes. 1:316–324. 2010. View Article : Google Scholar : PubMed/NCBI
|
